GRAIL, Inc. (GRAL) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Diagnostics & Research secteur d'activité. Le siège social de l'entreprise est situé à Menlo Park, CA, United States. Le PDG actuel est Robert Ragusa.
GRAL a date d'introduction en bourse 2024-06-12, 1,000 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $2.07B.
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
